SNDX
Syndax Pharmaceuticals, Inc. NASDAQ Listed Mar 2, 2016$19.35
+1.84%
vs $19.00
Mkt Cap $1.7B
52w Low $8.59
63.3% of range
52w High $25.59
50d MA $20.46
200d MA $19.50
P/E (TTM)
—
EV/EBITDA
—
P/B
25.9x
Debt/Equity
5.4x
ROE
-441.6%
P/FCF
-5.1x
RSI (14)
44.10
ATR (14)
$0.82
Beta
0.41
50d MA
$20.46
200d MA
$19.50
Avg Volume
1.8M
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
35 Gatehouse Drive · New York City, MA 02451 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | -0.59 | -0.48 | +18.6% | 21.43 | -2.8% | -10.8% | +4.4% | +0.7% | +2.7% | -0.5% | — |
| Feb 26, 2026 | AMC | -0.58 | -0.78 | -33.6% | 20.67 | -3.2% | +5.0% | +2.0% | -3.3% | +1.0% | -0.2% | — |
| Nov 3, 2025 | AMC | -0.74 | -0.70 | +5.4% | 13.76 | -1.2% | +11.6% | -1.6% | -2.7% | +2.4% | +4.5% | — |
| Aug 4, 2025 | AMC | -1.00 | -0.83 | +17.0% | 10.38 | +19.6% | +21.1% | +2.5% | -1.3% | -1.9% | +0.2% | — |
| May 5, 2025 | AMC | -1.04 | -0.98 | +5.8% | 13.57 | -4.2% | -21.6% | -6.1% | +10.2% | -2.8% | +2.7% | — |
| Mar 3, 2025 | AMC | -1.08 | -1.10 | -1.9% | 15.48 | -0.7% | -7.1% | +0.7% | -1.3% | -6.1% | -6.6% | — |
| Nov 5, 2024 | AMC | -1.13 | -0.98 | +13.3% | 19.69 | +9.7% | +8.4% | +0.8% | +1.3% | -0.1% | -25.6% | — |
| Aug 1, 2024 | AMC | -0.91 | -0.80 | +12.1% | 22.00 | -5.1% | -4.4% | -6.6% | +1.2% | -1.9% | +2.4% | — |
| May 8, 2024 | AMC | -0.96 | -0.85 | +11.5% | 22.38 | +1.2% | -1.8% | -1.0% | -3.6% | +3.3% | +1.3% | — |
| Feb 27, 2024 | AMC | -0.99 | -1.00 | -1.0% | 24.41 | -1.2% | -2.2% | -1.8% | +1.2% | -1.7% | -1.5% | — |
| Nov 2, 2023 | AMC | -0.80 | -0.73 | +8.8% | 14.78 | +0.9% | +0.1% | -2.7% | +1.5% | -3.6% | -4.4% | — |
| Aug 3, 2023 | AMC | -0.73 | -0.64 | +12.3% | 20.35 | +0.7% | -2.9% | -6.5% | -1.2% | +2.2% | -1.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Barclays | Maintains | Overweight → Overweight | — | $21.43 | $20.83 | -2.8% | -10.8% | +4.4% | +0.7% | +2.7% | -0.5% |
| Apr 1 | Goldman Sachs | Maintains | Buy → Buy | — | $23.36 | $23.91 | +2.4% | +2.2% | +5.3% | -3.4% | +1.4% | -0.3% |
| Mar 31 | Mizuho | Maintains | Outperform → Outperform | — | $22.48 | $23.48 | +4.4% | +3.9% | +2.2% | +5.3% | -3.4% | +1.4% |
| Mar 9 | JP Morgan | Maintains | Overweight → Overweight | — | $22.07 | $22.53 | +2.1% | +8.2% | +1.2% | +1.2% | -1.8% | -2.0% |
| Mar 2 | Citigroup | Maintains | Buy → Buy | — | $21.71 | $21.61 | -0.5% | +2.0% | -3.3% | +1.0% | -0.2% | +2.3% |
| Jan 27 | Mizuho | Maintains | Outperform → Outperform | — | $21.40 | $21.16 | -1.1% | -0.4% | -3.6% | +0.2% | -1.4% | +5.1% |
| Dec 9 | BTIG | Maintains | Buy → Buy | — | $19.98 | $19.95 | -0.2% | -2.4% | +5.7% | -1.0% | -0.2% | +2.5% |
| Nov 24 | Barclays | Maintains | Overweight → Overweight | — | $17.44 | $18.13 | +4.0% | +13.3% | -1.6% | +2.2% | -0.3% | -3.5% |
| Nov 12 | JP Morgan | Maintains | Overweight → Overweight | — | $17.73 | $17.56 | -1.0% | -5.3% | -0.8% | -0.2% | +3.4% | -0.5% |
| Nov 4 | UBS | Maintains | Buy → Buy | — | $13.76 | $13.60 | -1.2% | +11.6% | -1.6% | -2.7% | +2.4% | +4.5% |
| Nov 4 | Barclays | Maintains | Overweight → Overweight | — | $13.76 | $13.60 | -1.2% | +11.6% | -1.6% | -2.7% | +2.4% | +4.5% |
| Oct 27 | BTIG | Maintains | Buy → Buy | — | $13.53 | $13.39 | -1.0% | -3.1% | +3.1% | -2.1% | +1.3% | +2.3% |
| Oct 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.53 | $13.39 | -1.0% | -3.1% | +3.1% | -2.1% | +1.3% | +2.3% |
| Sep 19 | BTIG | Maintains | Buy → Buy | — | $15.45 | $15.51 | +0.4% | -4.3% | +0.7% | -0.3% | +1.1% | +0.1% |
| Sep 5 | Goldman Sachs | Maintains | Buy → Buy | — | $16.19 | $16.40 | +1.3% | +5.3% | -4.2% | -2.4% | -1.3% | +4.1% |
| Aug 5 | BTIG | Maintains | Buy → Buy | — | $10.38 | $12.41 | +19.6% | +21.1% | +2.5% | -1.3% | -1.9% | +0.2% |
| Aug 5 | Citigroup | Maintains | Buy → Buy | — | $10.38 | $12.41 | +19.6% | +21.1% | +2.5% | -1.3% | -1.9% | +0.2% |
| Jul 15 | UBS | Maintains | Buy → Buy | — | $9.85 | $9.90 | +0.5% | -6.5% | +0.4% | +4.5% | -2.2% | +2.9% |
| May 6 | Guggenheim | Maintains | Buy → Buy | — | $13.57 | $13.00 | -4.2% | -21.6% | -6.1% | +10.2% | -2.8% | +2.7% |
| May 6 | Scotiabank | Maintains | Sector Perform → Sector Perform | — | $13.57 | $13.00 | -4.2% | -21.6% | -6.1% | +10.2% | -2.8% | +2.7% |
| Mar 20 | JP Morgan | Maintains | Overweight → Overweight | — | $13.12 | $13.23 | +0.8% | +7.5% | -2.8% | +0.1% | -2.1% | -2.3% |
| Mar 4 | JP Morgan | Maintains | Overweight → Overweight | — | $15.48 | $15.37 | -0.7% | -7.1% | +0.7% | -1.3% | -6.1% | -6.6% |
| Mar 4 | Citigroup | Maintains | Buy → Buy | — | $15.48 | $15.37 | -0.7% | -7.1% | +0.7% | -1.3% | -6.1% | -6.6% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.48 | $15.37 | -0.7% | -7.1% | +0.7% | -1.3% | -6.1% | -6.6% |
| Jan 8 | Scotiabank | Maintains | Sector Perform → Sector Perform | — | $13.80 | $13.55 | -1.8% | +0.1% | -5.1% | -2.4% | -1.6% | +1.6% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.56 | $15.79 | +1.5% | -4.0% | -4.8% | -5.3% | +3.4% | -1.0% |
| Nov 21 | JP Morgan | Maintains | Overweight → Overweight | — | $15.95 | $16.06 | +0.7% | -2.2% | +3.1% | +4.0% | -1.4% | +0.1% |
| Nov 19 | Citigroup | Maintains | Buy → Buy | — | $16.11 | $16.13 | +0.1% | -2.1% | +1.1% | -2.2% | +3.1% | +4.0% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.83 | $16.46 | +4.0% | +1.8% | -2.1% | +1.1% | -2.2% | +3.1% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.78 | $16.27 | -25.3% | -25.6% | +2.6% | +1.0% | -5.7% | +1.8% |
| Nov 7 | Goldman Sachs | Maintains | Buy → Buy | — | $21.35 | $21.40 | +0.2% | +0.8% | +1.3% | -0.1% | -25.6% | +2.6% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.69 | $21.60 | +9.7% | +8.4% | +0.8% | +1.3% | -0.1% | -25.6% |
| Oct 14 | Stifel | Maintains | Buy → Buy | — | $19.13 | $19.06 | -0.4% | +3.6% | -0.4% | +0.7% | +0.0% | -0.9% |
| Aug 16 | Citigroup | Maintains | Buy → Buy | — | $19.96 | $20.03 | +0.4% | -0.2% | +2.9% | -0.3% | -0.6% | +0.0% |
| Aug 15 | BofA Securities | Maintains | Buy → Buy | — | $19.58 | $20.28 | +3.6% | +1.9% | -0.2% | +2.9% | -0.3% | -0.6% |
| Aug 15 | Barclays | Maintains | Overweight → Overweight | — | $19.58 | $20.28 | +3.6% | +1.9% | -0.2% | +2.9% | -0.3% | -0.6% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.58 | $20.28 | +3.6% | +1.9% | -0.2% | +2.9% | -0.3% | -0.6% |
| Aug 6 | JP Morgan | Maintains | Overweight → Overweight | — | $19.66 | $19.76 | +0.5% | +1.2% | -1.9% | +2.4% | +0.3% | -2.0% |
| Aug 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.00 | $20.88 | -5.1% | -4.4% | -6.6% | +1.2% | -1.9% | +2.4% |
| Jul 30 | BofA Securities | Maintains | Buy → Buy | — | $21.99 | $21.94 | -0.2% | +1.9% | +1.3% | -3.1% | -4.4% | -6.6% |
| Jul 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.49 | $20.97 | -14.4% | -10.2% | +1.9% | +1.3% | -3.1% | -4.4% |
| Jun 26 | Stifel | Maintains | Buy → Buy | — | $19.54 | $19.71 | +0.9% | +1.7% | +2.2% | +1.0% | +4.9% | -4.0% |
| Jun 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.11 | $20.00 | -0.5% | -1.1% | -4.1% | +1.1% | +4.0% | -1.2% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.21 | $19.10 | -0.6% | +1.0% | +0.5% | +1.1% | -2.0% | +4.9% |
| May 21 | JP Morgan | Maintains | Overweight → Overweight | — | $20.25 | $20.25 | +0.0% | +2.0% | +0.5% | -3.1% | +0.8% | -1.0% |
| May 9 | Stifel | Maintains | Buy → Buy | — | $22.38 | $22.65 | +1.2% | -1.8% | -1.0% | -3.6% | +3.3% | +1.3% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.38 | $22.65 | +1.2% | -1.8% | -1.0% | -3.6% | +3.3% | +1.3% |
| May 9 | Citigroup | Maintains | Buy → Buy | — | $22.38 | $22.65 | +1.2% | -1.8% | -1.0% | -3.6% | +3.3% | +1.3% |
| Apr 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.57 | $20.59 | +0.1% | +2.4% | +1.0% | -0.7% | +4.0% | -0.5% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.07 | $23.18 | +0.5% | +3.2% | -0.1% | -2.1% | +2.1% | -4.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Metzger Michael A | Chief Executive Officer | Sell | 6,847 | $18.99 | $130K | 484,843 | -0.27% | +4.30% |
| Jun 1, 2026 | Goldan Keith A. | Chief Financial Officer | Sell | 1,177 | $18.99 | $22K | 139,252 | -0.27% | +4.30% |
8-K · 1.01
! Medium
Syndax Pharmaceuticals, Inc. -- 8-K 1.01: Equity Issuance
Jun 10
8-K · 5.02
!!! Very High
Syndax Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Jun 10
8-K
Syndax Pharmaceuticals, Inc. -- 8-K Filing
Jun 4
8-K
Syndax Pharmaceuticals, Inc. -- 8-K Filing
Syndax Pharmaceuticals surpassed $100 million in combined Q1 2026 sales for cancer drugs Revuforj and Niktimvo, demonstrating strong market traction and progress toward profitability.
Apr 30
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis from this incomplete filing excerpt. Please provide the full 8-K summary or the specific compensation details (such as executive pay changes, equity grants, or severance agreements) to enable proper stock impact assessment.
Apr 7
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A life sciences-focused executive with deep investment banking expertise joined one of these companies, potentially signaling strategic M&A activity or capital-raising plans ahead.
Mar 23
8-K
Syndax Pharmaceuticals, Inc. -- 8-K Filing
Syndax Pharmaceuticals achieved its third FDA approval in 2025, demonstrating strong R&D execution and advancing its commercial-stage cancer therapy pipeline.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Bank Of America Corp /de/ | 4,249,836 | $99M | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 3,822,579 | $89M | New | Mar 2026 |
| 3 | Deerfield Management Company, L.p. | 3,779,900 | $88M | New | Mar 2026 |
| 4 | Hood River Capital Management Llc | 2,354,285 | $55M | Added | Mar 2026 |
| 5 | Franklin Resources Inc | 2,150,079 | $50M | Reduced | Mar 2026 |
| 6 | Point72 Asset Management | 1,985,547 | $46M | Reduced | Mar 2026 |
| 7 | Morgan Stanley | 2,151,002 | $45M | Reduced | Dec 2025 |
| 8 | Vanguard Portfolio Management Llc | 1,737,141 | $41M | New | Mar 2026 |
| 9 | Bnp Paribas Asset Management Holding S.a. | 1,732,541 | $40M | Added | Mar 2026 |
| 10 | Soleus Capital Management, L.p. | 1,726,908 | $40M | Reduced | Mar 2026 |
| 11 | D.e. Shaw & Co | 1,601,896 | $37M | Added | Mar 2026 |
| 12 | Two Sigma Investments, Lp | 1,579,596 | $37M | Added | Mar 2026 |
| 13 | Nuveen, Llc | 1,494,645 | $35M | Added | Mar 2026 |
| 14 | Mpm Bioimpact Llc | 1,340,733 | $31M | — | Mar 2026 |
| 15 | Aisling Capital Management Lp | 1,316,806 | $31M | — | Mar 2026 |
| 16 | Woodline Partners Lp | 1,250,760 | $29M | — | Mar 2026 |
| 17 | Stempoint Capital Lp | 1,215,743 | $28M | New | Mar 2026 |
| 18 | Ubs Group Ag | 1,153,662 | $27M | Added | Mar 2026 |
| 19 | Bank Of New York Mellon Corp | 1,004,498 | $23M | Reduced | Mar 2026 |
| 20 | Ensign Peak Advisors, Inc | 990,969 | $23M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.71B
Enterprise Value
$1.60B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.55x
P/B
25.93x
P/S
7.72x
P/FCF
-5.09x
EV/EBITDA
—
Shares Out
86.6M
Financials (TTM)
Revenue
$217.2M
Net Income
-$243.2M
EBITDA
-$162.5M
Free Cash Flow
-$323.2M
Op Cash Flow
-$323.0M
EPS Basic
$-3.30
EPS Diluted
$-2.80
EPS Forward
$-1.80
Gross Margin
98.0%
Op Margin
-102.9%
Net Margin
-112.0%
Balance Sheet
Total Assets
$529.7M
Total Liab.
$465.1M
Total Equity
$64.6M
Cash
$394.1M
LT Debt
$345.0M
Book Value/Sh
$0.75
Debt/Equity
5.36x
Current Ratio
4.40
Quick Ratio
4.12
Returns & Growth
ROE
-441.6%
ROA
-53.9%
ROIC
-66.6%
Rev Growth YoY
+627.8%
EPS Growth YoY
+11.5%
Price Returns
2W
-4.7%
1M
-8.6%
3M
-9.8%
6M
-1.2%
12M
+85.9%
Technicals
52W High
$25.59
52W Low
$8.59
50d MA
$20.46
200d MA
$19.50
RSI (14)
44.10
ATR (14)
$0.82
Beta
0.41
Avg Volume
1.8M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$39.33
High
$45.00
Low
$35.00
Median
$38.00
Data updated apr 27, 2026 2:09am
· Source: financialmodelingprep.com